Literature DB >> 17151131

Monoclonal antibodies to phosphatidylinositol phosphate neutralize human immunodeficiency virus type 1: role of phosphate-binding subsites.

Bruce K Brown1, Nicos Karasavvas, Zoltan Beck, Gary R Matyas, Deborah L Birx, Victoria R Polonis, Carl R Alving.   

Abstract

Both a murine monoclonal antibody to phosphatidylinositol phosphate (PIP) and a human monoclonal antibody (4E10) that is known to have broadly neutralizing capabilities against primary isolates of human immunodeficiency virus type 1 (HIV-1) bound to PIP, as determined by enzyme-linked immunosorbent assay. Each of the antibodies had antigen subsite binding specificities in aqueous medium for small phosphate-containing molecules and for inositol. The anti-PIP monoclonal antibody inhibited infection by two HIV-1 primary isolates in neutralization assays employing primary human peripheral blood mononuclear cells. The data suggest that PIP or related lipids having free phosphates could serve as targets for the neutralization of HIV-1.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17151131      PMCID: PMC1797582          DOI: 10.1128/JVI.02011-06

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  34 in total

1.  HIV vaccine design and the neutralizing antibody problem.

Authors:  Dennis R Burton; Ronald C Desrosiers; Robert W Doms; Wayne C Koff; Peter D Kwong; John P Moore; Gary J Nabel; Joseph Sodroski; Ian A Wilson; Richard T Wyatt
Journal:  Nat Immunol       Date:  2004-03       Impact factor: 25.606

2.  Evidence for budding of human immunodeficiency virus type 1 selectively from glycolipid-enriched membrane lipid rafts.

Authors:  D H Nguyen; J E Hildreth
Journal:  J Virol       Date:  2000-04       Impact factor: 5.103

3.  Antibodies to lipids and liposomes: immunology and safety.

Authors:  Carl R Alving
Journal:  J Liposome Res       Date:  2006       Impact factor: 3.648

4.  Increased efficacy of HIV-1 neutralization by antibodies at low CCR5 surface concentration.

Authors:  Vidita Choudhry; Mei-Yun Zhang; Ilia Harris; Igor A Sidorov; Bang Vu; Antony S Dimitrov; Timothy Fouts; Dimiter S Dimitrov
Journal:  Biochem Biophys Res Commun       Date:  2006-08-04       Impact factor: 3.575

5.  Effects of CCR5 and CD4 cell surface concentrations on infections by macrophagetropic isolates of human immunodeficiency virus type 1.

Authors:  E J Platt; K Wehrly; S E Kuhmann; B Chesebro; D Kabat
Journal:  J Virol       Date:  1998-04       Impact factor: 5.103

6.  Specific phospholipid recognition by human immunodeficiency virus type-1 neutralizing anti-gp41 2F5 antibody.

Authors:  Silvia Sánchez-Martínez; Maier Lorizate; Katinger Hermann; Renate Kunert; Gorka Basañez; José L Nieva
Journal:  FEBS Lett       Date:  2006-04-17       Impact factor: 4.124

7.  Lipid composition and fluidity of the human immunodeficiency virus envelope and host cell plasma membranes.

Authors:  R C Aloia; H Tian; F C Jensen
Journal:  Proc Natl Acad Sci U S A       Date:  1993-06-01       Impact factor: 11.205

8.  ATP specifically bound as a hapten to a monoclonal anti-phospholipid antibody retains phosphate donor activity.

Authors:  N M Wassef; G M Swartz; B M Alving; C R Alving
Journal:  Biochem Biophys Res Commun       Date:  1993-01-29       Impact factor: 3.575

9.  Antibodies reactive with liposomal phospholipids are produced during experimental Trypanosoma rhodesiense infections in rabbits.

Authors:  R L Richards; J Aronson; M Schoenbechler; C L Diggs; C R Alving
Journal:  J Immunol       Date:  1983-03       Impact factor: 5.422

10.  Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies.

Authors:  James M Binley; Terri Wrin; Bette Korber; Michael B Zwick; Meng Wang; Colombe Chappey; Gabriela Stiegler; Renate Kunert; Susan Zolla-Pazner; Hermann Katinger; Christos J Petropoulos; Dennis R Burton
Journal:  J Virol       Date:  2004-12       Impact factor: 5.103

View more
  29 in total

Review 1.  Polyreactive antibodies in adaptive immune responses to viruses.

Authors:  Hugo Mouquet; Michel C Nussenzweig
Journal:  Cell Mol Life Sci       Date:  2011-11-02       Impact factor: 9.261

2.  Replication competent molecular clones of HIV-1 expressing Renilla luciferase facilitate the analysis of antibody inhibition in PBMC.

Authors:  Tara G Edmonds; Haitao Ding; Xing Yuan; Qing Wei; Kendra S Smith; Joan A Conway; Lindsay Wieczorek; Bruce Brown; Victoria Polonis; John T West; David C Montefiori; John C Kappes; Christina Ochsenbauer
Journal:  Virology       Date:  2010-09-21       Impact factor: 3.616

Review 3.  The membrane-proximal external region of the human immunodeficiency virus type 1 envelope: dominant site of antibody neutralization and target for vaccine design.

Authors:  Marinieve Montero; Nienke E van Houten; Xin Wang; Jamie K Scott
Journal:  Microbiol Mol Biol Rev       Date:  2008-03       Impact factor: 11.056

4.  Neutralizing and other antiviral antibodies in HIV-1 infection and vaccination.

Authors:  David C Montefiori; Lynn Morris; Guido Ferrari; John R Mascola
Journal:  Curr Opin HIV AIDS       Date:  2007-05       Impact factor: 4.283

5.  New cholesterol-specific antibodies remodel HIV-1 target cells' surface and inhibit their in vitro virus production.

Authors:  Zoltán Beck; Andrea Balogh; Andrea Kis; Emese Izsépi; László Cervenak; Glória László; Adrienn Bíró; Károly Liliom; Gábor Mocsár; György Vámosi; George Füst; Janos Matko
Journal:  J Lipid Res       Date:  2009-08-04       Impact factor: 5.922

6.  Role of HIV membrane in neutralization by two broadly neutralizing antibodies.

Authors:  S Munir Alam; Marco Morelli; S Moses Dennison; Hua-Xin Liao; Ruijun Zhang; Shi-Mao Xia; Sophia Rits-Volloch; Li Sun; Stephen C Harrison; Barton F Haynes; Bing Chen
Journal:  Proc Natl Acad Sci U S A       Date:  2009-11-11       Impact factor: 11.205

7.  Deficient synthesis of class-switched, HIV-neutralizing antibodies to the CD4 binding site and correction by electrophilic gp120 immunogen.

Authors:  Stephanie A Planque; Yukie Mitsuda; Vida Chitsazzadeh; Santhi Gorantla; Larisa Poluektova; Yasuhiro Nishiyama; Christina Ochsenbauer; Mary-Kate Morris; Gopal Sapparapu; Carl V Hanson; Richard J Massey; Sudhir Paul
Journal:  AIDS       Date:  2014-09-24       Impact factor: 4.177

8.  In-solution virus capture assay helps deconstruct heterogeneous antibody recognition of human immunodeficiency virus type 1.

Authors:  Daniel P Leaman; Heather Kinkead; Michael B Zwick
Journal:  J Virol       Date:  2010-01-20       Impact factor: 5.103

9.  Anti-phospholipid human monoclonal antibodies inhibit CCR5-tropic HIV-1 and induce beta-chemokines.

Authors:  M Anthony Moody; Hua-Xin Liao; S Munir Alam; Richard M Scearce; M Kelly Plonk; Daniel M Kozink; Mark S Drinker; Ruijun Zhang; Shi-Mao Xia; Laura L Sutherland; Georgia D Tomaras; Ian P Giles; John C Kappes; Christina Ochsenbauer-Jambor; Tara G Edmonds; Melina Soares; Gustavo Barbero; Donald N Forthal; Gary Landucci; Connie Chang; Steven W King; Anita Kavlie; Thomas N Denny; Kwan-Ki Hwang; Pojen P Chen; Philip E Thorpe; David C Montefiori; Barton F Haynes
Journal:  J Exp Med       Date:  2010-04-05       Impact factor: 14.307

10.  Optimization and validation of the TZM-bl assay for standardized assessments of neutralizing antibodies against HIV-1.

Authors:  Marcella Sarzotti-Kelsoe; Robert T Bailer; Ellen Turk; Chen-li Lin; Miroslawa Bilska; Kelli M Greene; Hongmei Gao; Christopher A Todd; Daniel A Ozaki; Michael S Seaman; John R Mascola; David C Montefiori
Journal:  J Immunol Methods       Date:  2013-12-01       Impact factor: 2.303

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.